$ARTV

2 stories mentioning ARTVUpdated 16d ago

Every FINWIRES story that references ARTV, newest first.

Artiva Biotherapeutics Reports Positive AlloNK Data Across Autoimmune Diseases at EULAR 2026

Artiva Biotherapeutics (ARTV) said Monday it highlighted clinical, safety and translational data for AlloNK presented at the European Alliance of Associations for Rheumatology 2026 Congress.The company said presentations across rheumatoid arthritis, Sjogren disease and systemic sclerosis highlighted AlloNK's potential to induce deep B-cell depletion and meaningful clinical responses in refractory patients.The company said rheumatoid arthritis data showed a 71% ACR50 response rate at six months in patients in its Phase 2a basket trial.Artiva said the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for AlloNK in combination with rituximab provides an expedited development pathway as it advances its planned Phase 3 program in refractory rheumatoid arthritis.Shares of the company were up 3.7% in premarket trading.

$ARTV

Sectors48d ago

Sector Update: Healthcare Stocks Steady Pre-Bell Friday

Healthcare stocks were steady pre-bell Friday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down a slight 0.1%.Grifols (GRFS) stock was up more than 2% after the company posted a higher Q1 adjusted profit.ANI Pharmaceuticals (ANIP) shares were up more than 4% after the company reported higher Q1 adjusted earnings and net revenue, and raised its 2026 outlook.Artiva Biotherapeutics (ARTV) stock was up more than 3% after the company priced its $300 million underwritten offering of common shares and pre-funded warrants.

$ANIP$ARTV$GRFS$IBB$XLV

Track with the FINWIRES app suite

FolioX

Track ARTV in your portfolio

WheelAI

Analyze ARTV options with the wheel strategy

StockInsider

See market sentiment on ARTV